Eagles were recognized for the work in the classroom and out on the water CHESTNUT HILL, Mass. – 10 members of the Boston ...

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...

FLAT ROCK, MI — Flat Rock Community Schools announced the top 10 graduates in the Flat Rock High School Class of 2025. The ...

We recently published a list of These 10 Stocks Boast Double-Digit Gains Amid Boring Market. Scholar Rock Holding Corporation ...

Shares of Scholar Rock Holding ( SRRK 13.36%) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 ...

Scholar Rock (NASDAQ: SRRK) has reported positive results from the phase 2 Embraze trial, demonstrating statistically ...

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

Shares of Scholar Rock climbed after the company disclosed what it called positive results from a Phase 2 study assessing its drug for weight loss. Shares rose 12% to $35.01 in pre-market trading ...

Scholar Rock (NASDAQ:SRRK) announced Wednesday that its lead candidate, apitegromab, in combination with Eli Lilly’s ...

Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment.